Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

Last updated: June 11, 2018
Sponsor: IlDong Pharmaceutical Co Ltd
Overall Status: Completed

Phase

3

Condition

Vascular Diseases

Williams Syndrome

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT02145104
ID_IDCV_1302
  • Ages 20-75
  • All Genders

Study Summary

The purpose of this study is to evaluate of efficacy and safety of cilinidipine plus valsartan and valsartan alone in patients with essential hypertension inadequately controlled on valsartan monotherapy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • essential hypertension patients whose blood pressure is not controlled before thestudy (sDBP≥90mmHg for drug-treated patients, sDBP≥95mmHg for drug-naive patients)

Exclusion

Exclusion Criteria:

  • sSBP≥80mmHg after 4weeks of valsartan 160mg treatment

  • has a history of hypersensitivity to dihydropyridines or angiotensin II receptorblockers

Study Design

Total Participants: 286
Study Start date:
June 17, 2014
Estimated Completion Date:
September 29, 2016

Connect with a study center

  • Seoul National University Bundang Hospital

    Seong Nam, Kyung-gi
    Korea, Republic of

    Site Not Available

  • Seoul National University Bundang Hospital

    Seongnam-si, Kyung-gi
    Korea, Republic of

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.